IP Library › Patent Application 15042892
Patent Application
App. No. 15/042,892

Use of Dipeptidyl Peptidase IV Effectors for Normalizing the Blood Glucose Level in Mammals

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/042,892
Abstract

The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.

Claims (7)

1 .- 7 . (canceled)

8 . A method for lowering elevated fasting blood glucose levels in mammals comprising administering a therapeutically effective amount of at least one inhibitor of Dipeptidyl Peptidase (DP IV) or enzymes having DP IV-like enzyme activity.

9 . The method according to claim 8 , wherein said at least one inhibitor is administered orally in combination with at least one carrier substance.

10 . The method according to claim 8 , wherein said at least one inhibitor is administered in multiple administrations.

11 . The method according to claim 8 , wherein the mammals demonstrate clinically inappropriate basal and post-prandial hyperglycemia.

12 . The method according to claim 8 , wherein the administration is for the prevention or alleviation of pathological abnormalities of metabolism of mammals such as glucosuria, hyperlipidaemia, metabolic acidosis and Diabetes mellitus.

13 . (canceled)